Management of Residual Masses of Testicular Cancer : Experience of our Department
Urology B Department of the University Hospital of Rabat, Morocco.
Himmi Yassir, Amine Slaoui, et al., “Management of Residual Masses of Testicular Cancer : Experience of our Department”, American Research Journal of Urology, Vol 6, no. 1, 2023, pp. 1-6.
Abstract
We performed a single-center retrospective study of all patients operated in our department for residual masses after chemotherapy between January 2005 and October 2021. The primary endpoints were the occurrence of intraoperative and postoperative complications and recurrence after surgery.
A total of 9 patients were included in our study. The mean age of our patients was 32 years. The primary lesion was located in the left testicle in 55.5% of the cases, non-seminomatous germ cell tumors in 33.3% and mixed germ cell tumors in 33.3%. In 55.5% of cases, it was a stage II. All our patients received at least 2 cycles of first-line chemotherapy and the tumor markers measured after chemotherapy were normal in 66.6% of cases.
The location of the residual mass was retroperitoneal in 77.7% of cases and the size was greater than 3 cm in all our patients. In our series all patients underwent extensive retroperitoneal lymph dissection by laparotomy. However, there were no intraoperative deaths.
The anatomopathological results of the lymphadenectomy were in favor of teratoma in 55.5% of cases. The main complication was anejaculation in 8 patients (88.8%) and one patient was lost to follow-up. The one-year follow-up was marked by a retro hepatic recurrence in one patient.
In spite of the small number of cases we have, our overall results are in line with those found in referent centres for this type of surgery, which is considered to be major.
A total of 9 patients were included in our study. The mean age of our patients was 32 years. The primary lesion was located in the left testicle in 55.5% of the cases, non-seminomatous germ cell tumors in 33.3% and mixed germ cell tumors in 33.3%. In 55.5% of cases, it was a stage II. All our patients received at least 2 cycles of first-line chemotherapy and the tumor markers measured after chemotherapy were normal in 66.6% of cases.
The location of the residual mass was retroperitoneal in 77.7% of cases and the size was greater than 3 cm in all our patients. In our series all patients underwent extensive retroperitoneal lymph dissection by laparotomy. However, there were no intraoperative deaths.
The anatomopathological results of the lymphadenectomy were in favor of teratoma in 55.5% of cases. The main complication was anejaculation in 8 patients (88.8%) and one patient was lost to follow-up. The one-year follow-up was marked by a retro hepatic recurrence in one patient.
In spite of the small number of cases we have, our overall results are in line with those found in referent centres for this type of surgery, which is considered to be major.
Keywords
Testis; Retroperitoneal lymphadenectomy ; Residual mass.
